Merck KGaA Drops Oral MS Drug Cladribine Following FDA Meeting

Merck KGaA is abandoning its approval efforts for its oral multiple sclerosis (MS) drug cladribine after a meeting with the FDA, and it is pulling the drug from markets where it is already approved.
Washington Drug Letter